CNSP — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-08-12

• The following sets forth our results of operations (in thousands):

• Research and development expenses was approximately $1.2 million for both the three months ended June 30, 2026 and 2025, respectively. The decrease of $0.6 million in clinical costs related to Berubicin is offset by an increase in headcount and related expenses of $0.6 million. R&D expense includes …

• General and administrative expense was approximately $1.5 million and $1.2 million for the three months ended June 30, 2026 and 2025, respectively. The increase of $0.3 million in general and administrative expense was attributable to increases in headcount related expenses of $0.6 million, which is…

• Other income (expense) was approximately $0.1 million and $0.03 million for the three months ended June 30, 2026 and 2025, respectively. The increase in other income was mainly due to an increase in interest income due to higher cash balances in our money market accounts.

• The following sets forth our results of operations (in thousands):

Text removed vs the prior filing · source: 10-Q · 2026-05-14

• Results of Operations for the Three Months Ended March 31, 2026 Compared to the Three Months Ended March 31, 2025 (rounded to the nearest thousand):

• General and administrative expense was approximately $1,431,000 for the three months ended March 31, 2026 compared to approximately $1,095,000 for the comparable period in 2025. The increase in general and administrative expense was attributable to increases of approximately $31,000 in advertising a…

• Research and development expense was approximately $3,544,000 for the three months ended March 31, 2026 compared to approximately $3,243,000 for the comparable period in 2025. The change in research and development expense during the period is primarily attributable to an increase in professional ex…

• The net loss for the three months ended March 31, 2026 was approximately $4,937,000 compared to approximately $4,301,000 for the comparable period in 2025. The change in net loss is primarily attributable to increased research and development costs and increase in professional expenses.

• On March 31, 2026, we had cash of approximately $2,951,000 and we had a working capital deficit of approximately $504,000. We have historically funded our operations from proceeds from debt and equity sales.

Text added vs the prior filing · source: 10-Q · 2026-08-12

• We maintain a set of disclosure controls and procedures designed to ensure that material information required to be disclosed in our filings under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that material informa…

• Under the supervision, and with the participation of our management, including our chief executive officer and our chief financial officer, we conducted an evaluation of the effectiveness, as of June 30, 2026, of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) und…

• Based upon such evaluation, our chief executive officer and our chief financial officer have concluded that, as of June 30, 2026, our disclosure controls and procedures were, and continue to be, ineffective because of the material weaknesses in our internal control over financial reporting due to la…

• A material weakness is a control deficiency (within the meaning of the Public Company Accounting Oversight Board (“PCAOB”) Auditing Standard 1305) or combination of control deficiencies that result in a reasonable possibility that a material misstatement of the annual or interim financial statements…

Text removed vs the prior filing · source: 10-Q · 2026-05-14

• Our chief executive officer and our chief financial officer are responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f). Management conducted an assessment of the effectiveness of our internal control ov…

• A material weakness is a control deficiency (within the meaning of the Public Company Accounting Oversight Board (“PCAOB”) Auditing Standard 1305) or combination of control deficiencies that result in more than a remote likelihood that a material misstatement of the annual or interim financial state…

Text added vs the prior filing · source: 10-Q · 2026-08-12

• On August 11, 2026, Michal Fisher was nominated and appointed to serve as a member of our Compensation Committee. Ms. Fisher was appointed to our Board of Directors on May 4, 2026.

• On August 12, 2026, the Company entered into indemnification agreements with each of its directors and executive officers.

Text removed vs the prior filing · source: 10-Q · 2026-05-14

• On May 13, 2026, the Company and Christopher Downs, the Company’s Senior Vice President – Finance, entered into a Separation and Severance Agreement, which memorializes the terms of Mr. Down’s separation from service with the Company. Pursuant to the agreement, subject to Mr. Down’s timely execution…